Engineers Gate Manager LP Clovis Oncology, Inc. Transaction History

Engineers Gate Manager LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.05 - $2.85 $16,995 - $46,130	-16,186 Reduced 54.7%	13,406 $16,000
Q2 2022 Aug 15, 2022	BUY	$0.63 - $2.96 $18,642 - $87,592	29,592 New	29,592 $53,000
Q1 2022 May 16, 2022	SELL	$1.43 - $3.14 $23,993 - $52,686	-16,779 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.76 $45,303 - $79,868	16,779 New	16,779 $45,000
Q3 2021 Nov 15, 2021	SELL	$4.06 - $5.8 $163,617 - $233,740	-40,300 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$5.02 - $7.05 $202,305 - $284,115	40,300 New	40,300 $234,000
Q4 2020 Feb 16, 2021	SELL	$4.13 - $6.41 $109,445 - $169,865	-26,500 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$4.82 - $7.72 $299,804 - $480,184	-62,200 Reduced 70.12%	26,500 $154,000
Q2 2020 Aug 17, 2020	BUY	$5.69 - $9.69 $405,002 - $689,714	71,178 Added 406.22%	88,700 $599,000
Q1 2020 May 15, 2020	BUY	$3.77 - $11.0 $25,341 - $73,942	6,722 Added 62.24%	17,522 $111,000
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $101,400 - $555,334	-33,800 Reduced 75.78%	10,800 $113,000
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $116,461 - $454,881	29,634 Added 198.01%	44,600 $175,000
Q2 2019 Aug 14, 2019	BUY	$12.81 - $25.67 $191,714 - $384,177	14,966 New	14,966 $223,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.